Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase

Anticancer Drug Des. 1997 Jul;12(5):409-20.

Authors

S P Henry¹, D Monteith, F Bennett, A A Levin

Affiliation

¹ Isis Pharmaceuticals, Inc., Carlsbad, CA 92008, USA. [email protected]

PMID: 9236856

No abstract available

Publication types

Review

MeSH terms

Animals
Enzyme Inhibitors / pharmacokinetics*
Enzyme Inhibitors / toxicity*
Humans
Isoenzymes / antagonists & inhibitors*
Oligonucleotides, Antisense / pharmacokinetics*
Oligonucleotides, Antisense / toxicity*
Protein Kinase C / antagonists & inhibitors*
Protein Kinase C-alpha
Protein Serine-Threonine Kinases / antagonists & inhibitors*
Proto-Oncogene Proteins / antagonists & inhibitors*
Proto-Oncogene Proteins c-raf
Thionucleotides / pharmacokinetics*
Thionucleotides / toxicity*

Substances

Enzyme Inhibitors
Isoenzymes
Oligonucleotides, Antisense
Proto-Oncogene Proteins
Thionucleotides
Protein Serine-Threonine Kinases
Proto-Oncogene Proteins c-raf
PRKCA protein, human
Protein Kinase C
Protein Kinase C-alpha